Artivion (NYSE:AORT) SVP Andrew Green Sells 1,493 Shares

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 1,493 shares of the company’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.02, for a total value of $38,847.86. Following the transaction, the senior vice president directly owned 51,640 shares of the company’s stock, valued at $1,343,672.80. This represents a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Artivion Stock Down 0.1%

Shares of Artivion stock opened at $25.59 on Friday. The firm has a market cap of $1.25 billion, a PE ratio of -365.52 and a beta of 1.25. The business’s 50 day simple moving average is $26.09 and its 200 day simple moving average is $29.21. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. Artivion, Inc. has a 52-week low of $19.16 and a 52-week high of $48.25.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. On average, analysts predict that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AORT has been the topic of several recent analyst reports. Weiss Ratings lowered Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Citizens Jmp cut their price target on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. Citigroup reissued a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Canaccord Genuity Group upped their target price on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Finally, Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $44.83.

Institutional Trading of Artivion

Hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd bought a new stake in shares of Artivion during the 3rd quarter worth about $27,000. Rockefeller Capital Management L.P. lifted its position in Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after acquiring an additional 399 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after acquiring an additional 563 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after acquiring an additional 538 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Artivion in the fourth quarter valued at approximately $79,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.